Try our Advanced Search for more refined results
Life Sciences - June, 2021
379 articles
- 3 Highlights From NY Opioid Trial's 2nd Day
- Reps Urge DOJ To Deny Sacklers Releases In Purdue Ch. 11
- Okla. Judge Won't Certify Midcase Appeal In Opioid Bellwether
- After AMG Loss, FTC Can't Get Money Award In False-Ad Suit
- Pension Fund Sues BioPharma Board Over COVID Vax Fiasco
- As Medical Pot Sales Begin, SD Gov. Releases Cops' Policy
- Cancer Patients Can't Use Psilocybin Therapy, DEA Argues
- COVID-19 IP Waiver Supporters Splinter On What To Cover
- Key Opioid Study 'Of Zero Assistance,' Doctor Testifies
- Pot Software Co. Says Contract Suit Counterclaims Too Thin
- Gilstrap Says Patent Suit Was Filed Right On Time
- Carolina Casualty Ordered To Pay $17M Arbitration Award
- Teva Says Intas Unit Seeks Cancer Drug Generic Far Too Soon
- State Courts' Stark Lack Of Diversity Demands Action
- Ropes Assists As Vistria Nabs $2.7B For 4th PE Fund
- Facing 1st Jury, Opioid Attys Turn To Instagram, 'Wizard Of Oz'
- Drug Cos. Share Blame For Opioid Crisis, NY Jury Told
- High Court Limit On Patent Challenges To Spur More Fights
- Tech Giants Say TransUnion Ruling Backs PTAB Review Fight
- Trevena Investors Ink $8.5M Deal Over Painkiller Claims
- Ruling Needed Now On Calif. Pay-For-Delay Law, Court Told
- What COVID-19, Social Issues Mean For Pharma Case Juries
- Bankrupt Purdue Pitches $5.39M Exec Payment Plan
- Fla. Judge Wants More On Fraud Claims In $1B Herbalife Suit
- CD&R Makes Increased £2.8B Bid For UDG Healthcare
- Teva Seeks To Revoke IP For J&J Unit's Schizophrenia Drug
- Justices Narrow Bar On Patent Attacks By Inventors
- Opioids Were Mission Of 'Mercy' For Doctors, Expert Testifies
- Takeda Hit With Antitrust Suit Over IBS Drug Amitiza
- Supreme Court Clears Arthrex Docket With Mixed Rulings
- Pa. Woman Too Late To Add 2nd Product To Pelvic Mesh Suit
- Detroit Will Face Trial In Suit Over Medical Pot Raid
- Pharma Co. Says Contract Fight Can't Be Painted As Fraud
- Vaccinated Attys, Witnesses Can Go Maskless At Calif. IP Trial
- 6 Ways To Guide Applications Under New Patent Classification
- Jury Quick To Find Trader Guilty In Illumina Insider Case
- Justices Won't Weigh In On FCA Whistleblower Standard
- Juul Reaches $40M Deal With NC Over Teen Vape Marketing
- Giuliani Suspension Highlights Ethical Pitfalls For All Lawyers
- 3rd Circ. Asks Pa. Justices To Take Up Device Liability Row
- J&J Strikes $230M Opioid Deal With NY AG, Exits Trial
- Judge Rips 'Misleading' Fee Bid In Echo Of State St. Case
- Novartis Says Genentech Won't Return $210M IP Overpayment
- 3 Pharmacies Cut From NY Opioid Trial, CVS Reaches Deal
- NY Feds Say Trader Sought 'Illegal Edge,' Driven By Greed
- Pharma Co. Sues Insurer For Coverage In Opioid Suits
- Mylan Nabs Partial Win On EpiPen Claims, Still Faces Trial
- Israeli Trader Pleads Guilty In Insider Trading Ring
- B. Braun Pushes For Dismissal In PA Cancer Emissions Cases
- PTAB Won't Hear 2 Daiichi PGRs On Cancer Antibody IP
- Health Hires: Sheppard Mullin, Williams Mullen
- Earlier Suit May Void Gilead Whistleblowers' Kickback Claims
- Hemp Tea Co. Won't Dodge THC Suit On Residency Basis
- Latham, Simpson Thacher Rep Car Wash Co.'s $563M IPO
- NJ Attorneys Urged To Avoid Paying For Client Referrals
- Top Product Liability Cases Of 2021: Midyear Report
- J&J's Appeal Of $29M Talc Verdict Meets Skeptical Judges
- 5 Key Details To Know Before Epic Opioid Trial Starts In NY
- FlatWing Denied Atty Fees In Patent Fight With Pfizer Unit
- WTO Panel Debates EU's Alternative To IP Waiver Proposal
- 11th Circ. Backs Pfizer Unit's Win Over False Ad Suit
- Hemp Trade Group Says Farm Bill Legalized Delta-8-THC
- Deals Rumor Mill: Parexel, Hanon Systems, EssilorLuxottica
- Ford Ruling Affirms Basic Principles Of Personal Jurisdiction
- Otsuka Hits Indian Pharma Co. With IP Suit Over Kidney Drug
- Insider Trading Suspect Spars With Gov't At Illumina Trial​​​​​​​
- Medline Accused Of Trying To Hurt Rival With Disinformation
- Boston Firm Choate Adds Ex-GE Counsel To IP Group
- Goodwin-Led Medical App Doximity Prices $606M IPO
- 4th Circ. Undoes $22M Defamation Verdict Against Biotech Co.
- AstraZeneca Sues Cancer Research Co. Over License Breach
- 9th Circ. Is Wrong On Consumer Fraud Injunctive Relief Issue
- Wis. Opioid Settlement Measure Clears State Legislature
- Tax Court Judge Probes Averaging Pricing In Medtronic Trial
- Ex-Mallinckrodt Rep Loses Sanctions Bid In Acthar Suit
- Biopharma Wins $1 In Del. IP Suit Over Ex-CEO's Wrongdoing
- Women Arguing Far Fewer Patent Appeals For Cos. Than Men
- Calif. Jury Clears CVS In $121M Drug Overcharge Trial
- GSK Unveils Long-Awaited Consumer Health Spinoff Plans
- Where FCA Litigation Stands 5 Years After Escobar
- Anticipating Patent System Change-Ups Under Biden
- Televangelist Bakker To Pay $156K Over COVID Cure Claim
- Rimon Makes Inroads In Delaware With IP Hire
- Judge Backtracks On Juror Vaccine Mandate In Opioid MDL
- To Reduce Prescription Prices, Hold Middlemen Accountable
- Holland & Knight Lures Troutman Pepper Partner To Dallas
- Merchant & Gould Taps Two Partners To Lead Practice Group
- Ex-AstraZeneca Rep Wins $2.4M Verdict On Retaliation Claim
- Calif. Judge Rips Monsanto's Atty In $87M Roundup Appeal
- CVS Drug Buyers Seek $121M As Overcharge Jury Trial Wraps
- Imerys Talc Says New Ch. 11 Acquisition Plan Lowers Risk
- Senate Panel Hears 'Disturbing Reality' On Patent Quality
- In Arthrex, Justices Deal New Blow To Agency Independence
- Rhode Island Senate OKs Legalizing, Taxing Cannabis
- Claims Court Explains Why VA Can't Revisit Contract Transfer
- IHS Urges DC Circ. Not To Revisit Tribal Health Costs Ruling
- Teva Settles Mississippi Drug Price-Fix Claims For $925K
- Abbott, Ex-Worker End COVID-19 Tests TM Suit
- Ex-MiMedx CFO Claims Ignorance In Securities Fraud Suit
- Neutrogena Sued Over Claims Sunscreen Contains Benzene
- 5 Practical Takeaways From High Court Arthrex Ruling
- Navigating Inadvertent Attorney-Client Privilege Waivers
- Fed. Circ. Will Return To In-Person Arguments In August
- How SPACs Should Respond To Increasing Scrutiny
- Coronavirus Regulations: A State-By-State Week In Review
- Calif. Bill Would End Damages Injustice For Dead Plaintiffs
- Vaccine Mandate May Skew Opioid MDL Jury, Pharmacies Say
- Chinese Drug Co. Chief Must Testify In Tainted Valsartan MDL
- Ex-FDA Chief Counsel Moves To MoFo To Co-Lead Practice
- Morgan Lewis Bows Out Of Price-Fix Case After Conflict Claim
- DuPont Can't Shake Pension Eligibility ERISA Suit
- Arthrex Ruling Leaves Attys Eyeing USPTO For Guidance
- CVS Didn't Need To Report Drug Discounts To PBM, Jury Told
- Ga. Supplement Seller Admits To Selling Unapproved Steroids
- New Arthrex Powers Put Spotlight On USPTO Director Search
- Crowell & Moring Can't Nix Walgreens' Malpractice Suit
- DOL Seeks Employers' Input On Drug Cost Disclosure Policy
- Court Bars Mo. From Enforcing Residency Rules For Pot Cos.
- IRS' IP Pricing In Medtronic Case Untenable, Witness Says
- Pharma Co. Can't Shake €140M AOP Orphan Award Yet
- Fed. Circ. Won't Eye Amgen Case But Disputes 'Sky Is Falling'
- Judge Blasts 'Breathtaking' Atty Fee Bid In Roundup MDL
- Ex-Univar Exec Fights Claim He Owed Notice About Job Hunt
- Okla. Pot Co. Pushes Back In Seed-To-Sale Tracking Challenge
- Health Cos. Must Prepare For Growing Ransomware Threat
- Entwistle, Wolf Haldenstein Vie To Rep Emergent Investors
- High Court Skips Amgen Unit's Arthrex Arguments In IP Case
- Fenwick-Led Cybersecurity Firm Unveils Plans For $880M IPO
- High Court Declines To Review Amarin's Vascepa Fight
- Health Network Sues For Coverage Of Scientist's $10M Award
- Justices Won't Hear Ax of Medtronic Suit In $112M IP Dispute
- A Practical Metric For Annual Patent Filing Targets: Part 2
- Attorneys Beware: Zoom Depositions Are Likely Inadmissible
- High Court Won't Hear Sham Litigation Exception Case
- Justices Add More Oversight To PTAB In Arthrex Ruling
- HHS Pulls Pharmacy Discount Rule Amid Litigation Barrage
- US Chamber Urges Justices To Review NY Opioid Tax Row
- Canadian Hemp Co. Says Seed Dispute Is In Wrong Court
- Biden Loosens Sanctions For COVID-19 Equipment Shipments
- Meet Biden's HHS Watchdog Pick, Who Stoked Trump's Ire
- Mass. Pot Regulators Hit TILT, Ayr With Nearly $600K In Fines
- Health Hires: Sheppard Mullin, Elanco, Yumanity Therapeutics
- Bard Hit With $3M Verdict In Vein Filter Suit
- J&J Accused Of Seeking 'Secrecy' In Fired Exec's Bias Suit
- 4 Firms Lead Clinical Stage Atai For $3B Valuation In IPO
- GSK Gets Top Court Assist In MDL Victory 'Roadmap'
- Munger Tolles 3 Years Ago Quietly Set Stage For ACA Win
- IP Forecast: Pro Wrestler Preps For Video Game Trial
- Claims Court Won't Let VA Revise Med. Supply Deal Transfer
- Walmart CEO Faces Opioid MDL Grilling Despite Protest
- Ex-Merck Sales Rep Asks 9th Circ. To Revive Kickback Fight
- LegitScript Fights Bid To Move Antitrust Claim To Oregon
- Detroit Pot Licensing Scheme 'Likely Unconstitutional'
- Contract Rights Vs. Patent Invalidity: 2 Key Cases To Watch
- Del. Judge OKs Mallinckrodt Toss Of Ill. City's Ch. 11 Claims
- Cooley-Led Biotech Firm Leads 4 IPOs Totaling $847M
- Sens. Advance BigLaw Picks For Fed. Circ., DOJ Criminal Div.
- Telehealth Must Contend With Compounded Medication Regs
- Cosmetics Trade Group Escapes J&J Asbestos-In-Talc MDL
- HHS Chief Faces Call To Fire FDA Brass After Biogen Approval
- NJ Fed. Court Should Ditch Litigation Funding Disclosure Plan
- Deals Rumor Mill: Didi Chuxing, Azelis, EBay
- ACA Survives Latest Republican Challenge At Supreme Court
- Kirkland, Simpson Steer Danaher's $9.6B Aldevron Buy
- Gilead Ruling Guts Investors' Rights, Calif. Appeals Court Told
- Escobar 5 Years Later: How FCA Earthquake Is Reverberating
- Del. Judge Rejects 'Flawed' HHS Pharmacy Discount Rule
- NJ Justices Revive Ex-Pharma Exec's Racial Slurs Claim
- HHS Secretary Becerra Defends $132B Budget Request
- Examiner With Narrow Scope Approved In Purdue Ch. 11
- NYC Doc Gets Over 4½ Years For Taking Insys Kickbacks
- Insurance Language Lesson From An Opioid Ruling
- Latham-Led AI Startup Leads 3 IPOs Raising $538M Combined
- GSK Denied Restitution In Trade Secrets Theft Case
- 3 Firms Aid On $2B SPAC Deal For Firefighting Chemicals Co.
- Complying With New EU Data Transfer Contractual Obligations
- Trader Pushes Back Against Witness In Illumina Insider Trial
- Law Firm Talent Must Reflect Shifting US Demographics
- Cannabis SPACs Are Piquing Investor Interest
- New York Opioid Trial Delayed Again As Jury Selection Lags
- Greenberg Traurig Adds Faegre Drinker Pharma Litigation Vet
- 3rd Circ. Says Tolling Rule Saves Valeant Investors' Claims
- Covington, MoFo Steer Elanco's $440M Pet Pharma Co. Buy
- Thorny Issues Posed By WTO Vaccine Patent Waiver
- Kodak CEO Ordered To Testify In NY's Insider Trading Probe
- Elizabeth Holmes Can't Probe Jurors On Media Consumption
- Mallinckrodt Ch. 11 Plan Disclosure Challenges Shot Down
- Gilead Wants Whistleblowers' Drug Rx Kickback Suit Killed
- Zimmer Biomet Says Fatal Flaws Doom $3B Del. Cashout Suit
- Drugmakers Can't End Calif. Opioid Trial, Judge Rules
- Watchdog Questions Imerys Talc's Ch. 11 Asset Buy Plans
- Genentech Can't Shake Ex-Worker's 401(k) Fee Suit
- Coronavirus Regulations: A State-By-State Week In Review
- Chancery OKs Trimmed $3.45M Fee In Nutraceutical Sale Suit
- Trader Tells Jury He Got No Illegal Info From Scared CPA
- VA's OIG Says PPE Plans Created Pre-COVID Weren't Utilized
- W.Va. State Opioid Claims Will Be Heard By A Jury
- Centene Settles Ohio, Miss. PBM Claims, Sets Aside $1.1B
- Bio-Rad Points To Worker Pacts In Battling 10X Fed. Circ. Win
- $1.8B Biotech Sale Targeted In 3 Delaware Class Suits
- Peruvian Medical Co. Says German Co. Can't Ditch Virus Suit
- CVS Overcharged Insured Drug Buyers $123.7M, Jury Told
- Glenmark, Teva In No Rush For January 2022 Criminal Trial
- Indiana Doctor's Suit Targets 'Monopolist' IU Health System
- Insulin Makers Blast Patients' 3rd Bid For RICO Claims
- Cooley-Led Customer Software Firm Leads 9 IPO Launches
- RI Senate Panel OKs Legalizing, Taxing Cannabis
- Insulin Pen Buyers Can Name Sanofi's Puerto Rico Unit In Suit
- Biden Keeps Trump's Proposal To Curb March-In Rights
- Mallinckrodt Says Ch. 11 Disclosures Have Enough Info
- Anesthesiology Group Aims To Sink Libel Suit Over Articles
- Patients Get Class Cert In Aetna Disc Surgery Lawsuit
- Justices Won't Review Doc's Conviction For Drug Trial Trades
- Purdue Hits Back At Creditor's Motion For Ch. 11 Examiner
- Judges Should Foster Diversity In MDL Leader Appointments
- Allergan Unit Must Face Bulk Of Namenda Pay-For-Delay Suit
- Mallinckrodt Creditors Question Ch. 11 Drug Sale Process
- Ex-CVS Exec Probed On Drug Prices In Overcharge Trial
- Quest Diagnostics Escapes Amazon Temp Worker's Pot Suit
- Insurer Needn't Help Cover $20M Award From Akorn Meds Suit
- Endo Can't Shake FTC Pay-For-Delay Suit, Judge Told
- Tenn. Appeals Court Won't Halt Endo's $2.4B Opioid Trial
- SEC Says Biotech Co. Tricked Investors Out Of Millions
- FDA's Alzheimer's Drug Approval Deepens Searing Debate
- Meet The Judge Overseeing The 1st Opioid Jury Trial
- Tivity Health Investors Seek Approval Of $7.5M Settlement
- Congress Should Step In To Solve The Opioid Crisis
- Brand Battles: Miracle-Gro Aims To Weed Out 'Gromeo' TM
- Medical Device Cases Show Increased Sunshine Act Scrutiny
- Roche Can't Beat $171M Judgment, Fed. Circ. Told
- Skadden-Led Chinese Recruiting Co. Tops Trio Raising $1.4B
- A Biz Strategy Model To Improve Lateral Atty Hiring Diversity
- Boston Hotel's Virus Policy Only Covered 2 Days, Insurer Says
- 2nd Circ. Rejects FTC Antitrust Case Against 1-800 Contacts
- Insys Seeks Ch. 11 Clawback Of $10M In Ex-CEO's Legal Fees
- UK Litigation Roundup: Here's What You Missed In London
- Calif. Counties Battle Drugmakers' Bid To Nuke Opioid Trial
- 9th Circ. Skeptical Of Researcher's Shot At DEA Pot Rule
- IP Forecast: Amazon To Face A Texas Jury Over Voice IP
- Freezer Co. Hit With $15M Verdict Over Destroyed Embryos
- Pa. Chemical Co. Says Patent Dispute Can't Be Arbitrated
- Judge Slams Calif. For Discovery Violation In Generics MDL
- US To Buy 500M Pfizer Vaccine Doses For Global Donation
- 5th Circ. Won't Revive Sanofi Chemo Hair Loss Suit
- CVS Pricing Practice 'Cheated' Insured Drug Buyers, Jury Told
- 2 Israeli Traders Charged In Global Insider Trading Ring
- Teva Gets Judge To Nix Drug IP Inventorship Correction Order
- Sandoz Will Get To Search Rival CFO's Phone In Antitrust Row
- 5 Steps To Successful Mass Tort Management
- How Legal Profession Can Help LGBTQ Patent Attys Thrive
- 2nd Circ. Weighs Insider Trading Raps Post-Bridgegate
- Monsanto's PCBs Caused Brain Damage, Teachers Tell Jury
- Ill. Court Rules Home Health Co. Took Kickbacks
- Lexicon Investors Urge 5th Circ. To Revive Diabetes Drug Suit
- Elizabeth Holmes' Privilege Loss 'A Cautionary Tale,' Attys Say
- COVID Vaccine IP Waiver Talks Heat Up At The WTO
- Goodwin, Latham Steer $2.8B Drug Discovery SPAC Deal
- ChemoCentryx Hit With Investor Suit Over Drug Trial Claims
- Boston Scientific Promotes Veteran Atty To General Counsel
- What Tax Court's Mylan Legal Fee Ruling Means For IP Suits
- Smaller Firms Need Employee Wellness Programs, Too
- MSP Recovery's Opioid Claims Consolidated With Ohio MDL
- Parkinson's Drug Patent Ax In Del. Helps Mylan Win In Vt.
- MDL Accusing Seed Cos. Of Price-Fixing Is Planted In Mo.
- Glenmark Says Glitch Calls For Supplement To DQ Testimony
- Hours After Getting Patents, Teva Sues Eli Lilly Again
- Wash. Pot Sellers Wary Of State's 'Joints For Jabs' Rules
- Aleut Org. Sues Juul For Unequal Impact On Alaska Natives
- 3rd Circ. Revives Trade Secrets Suit Against Aurobindo
- No Centralization Of Acthar Cases In Delaware Yet, JPML Says
- Pa. Panel OKs Unemployment Claim After Medical Pot Firing
- Tilray Settles Contract Dispute With Fla. Cannabis Grower
- FTC Says High Court Ruling Doesn't Doom Injunction Bid
- Judge Takes Ill. City's Attys To Task For Mallinckrodt Filings
- 'Job Sharing' Plan Not Required Under ADA, 4th Circ. Says
- 2 Firms Seek $3.75M For $17.5M Nutraceutical Suit Deal
- AGs Back Bid To Close Sackler Family's Liability Loophole
- Venable Picks Up Hatch-Waxman Trial Veteran
- Coronavirus Regulations: A State-By-State Week In Review
- China Trade Secret Developments Bring Certainty For US Cos.
- Biden Aims To Jolt Lagging Supply Chains
- Teva Fights To Invalidate Astellas' Urinary Drug Patent
- CBD Cream Seller Seeks Sanctions Over 'Frivolous' IP Claims
- Panel Rules Pfizer Can't Get New MDL Over Cancer Drug IP
- Fed. Circ. Mulls Mixed PTAB Rulings In Teva Antibody IP Fight
- CytoDyn Brass Hyped COVID Drug, Dumped Shares, Suit Says
- Perrigo Drug's Pricing Way Off, Expert Says In $163M Tax Trial
- Artificial Intelligence Startup Leads Wave Of 4 IPO Candidates
- Too Late To Change Hormone Pellet Complaint, Ill. Panel Says
- Justices Won't Hear Challenge To FDA Regulation Of E-Cigs
- Calif. Survival Damages Bill Would Cost Cos., Consumers
- Compliance Considerations For Pharma Co. Testing Programs
- How Ad Disputes Between Cos. Fuel Consumer Class Actions
- Cooley, Skadden Steer $2.1B Deal For Primary Care Provider
- What Semiconductor Shortage Means For Patent Drafting
- Horse-Doper's Light Sentence No 'Bellwether,' Judge Warns
- Clinical Trials Manager Settles SEC Insider Trading Suit
- Ex-Pharma Co. Workers Must Arbitrate Whistleblower Claims
- FDA OKs Biogen Alzheimer's Drug Despite Evidence Issue
- JPML Sends McKinsey Opioid Cases To New MDL
- Monsanto Asks 11th Circ. To Create Roundup Label Precedent
- Biotech Insider Gets 6 Mos. For Trading On Deal Talks
- Feds Attack Ex-Theranos CEO's 45-Page Juror Questionnaire
- Retailers, Generics Makers Want Out Of Zantac MDL
- B. Braun Medical Must Face ERISA Suit Over 401(k) Plan
- Classes Get Cert., Lose State Law Claims In Opana MDL
- NY AG Dodges Removal From Imminent Opioid Trial
- Okla. Medical Pot Rule Challenge Ends Over Pot's Illegality
- Opioid Bellwether Trials Against Pharmacies To Be Bifurcated
- FDA Details Drug Security Essentials In 4 Compliance Guides
- EU Won't Budge On COVID-19 Vaccine IP Waiver
- Cannabis Bill Roundup: Colo. Eyes New Caps On Pot Sales
- Health Hires: Nossaman, JCyte, Gravie, McCarter & English
- Fla. High Court Keeps Tight Grip On Medical Pot Licenses
- Bio-Rad Tries To Keep 10X From Talking Up Pandemic At Trial
- Feds Warn Of Biotech Exec's Next Stock Scam Without Prison
- Unpacking The Latest Trends In Biologics-Related IPRs
- Atty Fees Trimmed By $100K In Bluebird Bio Pay Suit
- Former J&J Exec's Workplace Bias Suit Sent To Mediation
- Stop Networking, Start Relationship Marketing
- When Your 9th Circ. Case Needs California High Court Input
- Hearing Loss Biotech Sued By Investor Over 78% Stock Drop
- Drugmakers Fire Torpedo At 'Centerpiece' Of Calif. Opioid Trial
- Patentees Get Boost With China's Version Of Hatch-Waxman
- Diet Supplements Violated TM With Steroid Link, Jurors Hear
- Drugmakers Urge Fla. Court To Trim Zantac MDL
- 1 Firm Eked Ahead Of Peers Amid Bumpy May IPO Market
- Ex-Theranos CEO Can't Have Atty Privilege Via Boies Schiller
- IP Forecast: Fed. Circ. Set To Drill Into Fracking Patent Fight
- Cherokee Tribe Calls McKinsey 'Ringleader' In Opioid Crisis
- Pot Shop Owner Must Share Profits With Aggrieved Ex-Partner
- Lawmakers Seek Probe Of USPTO Director's Sway Over PTAB
- Medical Pot User's Nixed Job Offer Allowed, Hospital Says
- FTC Can't Seek Restitution From Shkreli Until Congress Acts
- Elizabeth Holmes Wants 'Anecdotal' Evidence Blocked In Trial
- Shifting Trends In Marketing Approvals Of Orphan Drugs
- Firm Settles AG's Claim It Traded Referrals For Yacht Outing
- Health, Green Groups Push FDA To Ban PFAS
- Hearing Aid Implant Maker Mostly Wins At PTAB Against Rival
- Purdue Asks To Extend Opioid Suit Shield To End Of Summer
- McKesson, Fla. Pharmacy Chain Settle $7M Contract Row
- What Attorneys Should Know About Fee Deferral
- Pharmacist Says 8 Years Enough For Lab Outbreak Scandal
- Emergent Faces Investor Suit Over Destroyed COVID Vaccines
- 11th Circ. Won't Lift Stem Cell Clinic Ban
- Ark. Pot Agency Wants Out Of City's Row With Harvest Health
- Contractor Owes No Penalty After Slow Gov't Cost Cap Update
- CVS Judge Slams 'Totally Inappropriate' Trial Instructions
- Anthem Patient Wants 9th Circ. Revival Of Device Denial Suit
- Insurer Dodges Cryotherapy Clinic's Virus Coverage Suit
- Wachtell, Skadden Guide MorphoSys' $1.7B Cancer Co. Buy
- Okla. Fights Challenge To State's Pot Tracking Method
- Predictions On Pandemic's Lasting Impact On Legal Education
- DNA Co. Says Calif. Standards Wrongly Used To Trim Suit
- Sen. Wyden Wants Answers On AbbVie's Int'l Tax Practices
- Fight On Tap Over Firms' $4M Fee Bid In CytoDyn Suit Deal
- Cos. Should Review Insurance Policies For PFAS Coverage
- AbbVie Asks Justices To Hear Sham Litigation Exception Case
- Shkreli Punished For Secret Phone But Can Deny Conspiracy
- Del. Chancery Keeps Alive Suit Over Tilray's PE Insider Deals
- FTC's Illumina-Grail Court Case Dropped Despite Cos.' Protest
- New Lead Atty In Opioid MDL Carries On 'Legacy' Of Hanly
- $30.2M Deal, $9.3M Fee Award Greenlit In Lens Price-Fix MDL
- Sanofi Urges 10th Circ. To Revive EpiPen Antitrust Case
- NY AG Demands Kodak Execs Testify In Insider Trading Probe
- Clarus Wins Ax Of Rival's Testosterone Patent Claims
- Fla. Nursery Urges 11th Circ. To Rule In Pot License Dispute
- VA Wants Suit Paused As It Revisits Deal With Defense Agency
- Jurors To Hear About Whistleblower's Lost Texts, Judge Says
- Global Orgs. Unite For COVID-19 Vaccine Distribution Push
- Gibson Dunn-Led Mesa West Lends $178M For Office Complex
- Cleaning Wholesaler Claims Hand Sanitizer Bait And Switch
- Key Ruling Foils GSK Zofran MDL Ahead Of Bellwether
- Sanofi Rips Fed. Circ. Rehearing Bid In Repatha IP Fight
- Roundup Case Shows State Law Can Top Preemption Defense
- Lawyer Perfectionism Is A Disease We Can Control
- Coronavirus Regulations: A State-By-State Week In Review
- Calif. Doc Can't Force CVS To Fill Opioid Prescriptions
- High Court Won't Hear J&J Challenge To $2.1B Talc Verdict